By Terri Conneran, Founder, KRAS Kickers Reviewed for clinical accuracy by Salman R. Punekar, MD, MSc, Perlmutter Cancer Center at NYU Langone Health For this daraxonrasib lung cancer study, eligible RAS mutations were found at G12, G13, or Q61. The exact gene and exact mutation still matter because different RAS mutations can behave differently and may affect treatment or clinical trial options. For example, KRAS G12D, KRAS G12V, and KRAS G12C are all RAS mutations, but they

Val’s Advice to Others Facing Lung Cancer ...a quiet but powerful advocate, offering guidance to other people, especially young adults with cancer: “Don’t freak out when you’re diagnosed. And don’t go straight to Google. Statistics don’t define you

..just been diagnosed—or are navigating next step—you’re not alone. Cancer care has changed dramatically in the last decade. Today, you may have more treatment choices than ever before. This post is designed to help you understand your options and feel confident asking the right questions.

Need to know what mutation is driving the cancer bus. It's different than noise from the back of the bus. Biomarkers testing tells us what to Aim for as the cancer driver, not the background noise. Taking out the cancer driver can make the difference. Biomarkers provide the insights as to what is driving the cancer.